Abbott cuts prices to VHA under renegotiated sole-source contract, adds Carpuject syringe to agreement.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT/VHA SUPPLY DEAL RENEGOTIATED IN RESPONSE TO PRICING PRESSURE for intravenous supplies and other products covered under the contract. Abbott's existing sole-source deal with VHA was set to expire in 1999, but VHA renegotiated the agreement in light of lower prices in markets covered by the deal. The supply pact includes I.V. supplies, parenteral nutritionals and compounding systems, electronic drug delivery systems, critical care products, and injectable drugs and delivery systems.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.